PEX14

Across TCGA pan-cancer cohorts, PEX14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PEX14 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PEX14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PEX14 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where PEX14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.661	0.865	.003	32	view →
LUAD	OS	Median	All	0.924	1.000	.002	19	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.363	.042	4	view →
HNSC	OS	Median	II,III,IV	0.797	0.641	.017	3	view →
CCRCC	OS	Median	All	0.656	1.000	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PEX14–PDAC (DFS)

Open the PDAC breakdown →